https://doi.org/10.4081/monaldi.2013.28

Roflumilast is safe and effective in improving symptoms and lung function in severe COPD

Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
Submitted: August 19, 2015
Accepted: August 19, 2015
Published: August 19, 2015
Roflumilast, COPD, Case report, Lung function
Abstract Views: 725
PDF: 583
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Matteo Bonini
Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Italy.
Paolo Palange
paolo.palange@uniroma1.it
Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Italy.
The case of a 66-year-old man with severe chronic obstructive pulmonary disease (COPD) is presented. Diagnosis was based on baseline pulmonary function tests (PFTs) and clinical examination. Therapy with tiotropium 18 μg (once daily) and salmeterol/fluticasone 50/500 μg (twice daily) failed to achieve optimal disease control. Roflumilast (Daxas) 500 μg once daily was therefore added and a progressive improvement in the patient’s condition was observed during the 1-year followup. In this patient with severe COPD, roflumilast represented a safe and effective therapeutic strategy for managing clinical symptoms and for significantly improving lung function parameters.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Bonini, Matteo, and Paolo Palange. 2015. “Roflumilast Is Safe and Effective in Improving Symptoms and Lung Function in Severe COPD”. Monaldi Archives for Chest Disease 79 (3-4). https://doi.org/10.4081/monaldi.2013.28.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.